One embodiment of the invention relates to a method to treat chordoma in an individual who has chordoma.

Conventional (or classic) chordoma is the most common form of chordoma.

Chordoma is a very rare tumor with an average survival of about six years after diagnosis.

This anomaly increases the risk of developing a chordoma but does not cause chordoma by itself.

This SNP causes an increase in the risk of developing chordoma, but does not by itself cause chordoma.

Changes in the TBXT gene have been associated with chordoma.

Very rarely, these cells turn into cancer called chordoma.

While chordoma can run in families, this is very rare (see “Are there risk factors for chordoma?” section below).

The ability to fund this research is the result of a community-driven partnership with the Chordoma Foundation based in the US and the Canadian Chordoma Network led by Steven Golick.

as part of the “public” (non-scientific summary), a chordoma relevance statement clearly describing the potential of this project to impact chordoma

For everyone in the chordoma community, this is huge.

Poorly differentiated chordoma is a recently identified subtype.

At any given time, fewer than one in 100,000 people are living with chordoma.

At any given time, it is estimated that fewer than one in 100,000 people are living with chordoma.

Where can I find information about diagnosis or management of heterotaxy syndrome?